Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15001544 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Andreozzi F, et al. (2004) Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells. Endocrinology 145, 2845-57 15001544
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S312-p - IRS1 (human) ▲
Orthologous residues
IRS1 (human): S312‑p, IRS1 (mouse): S307‑p, IRS1 (rat): S307‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE JNK1 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase High glucose concentrations (25 mM)
azaserine glucose inhibit treatment-induced increase High glucose concentrations (25 mM)
glucosamine increase
JNK inhibitor I glucosamine inhibit treatment-induced increase

Y612-p - IRS1 (human) ▲
Orthologous residues
IRS1 (human): Y612‑p, IRS1 (mouse): Y608‑p, IRS1 (rat): Y608‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
glucosamine insulin inhibit treatment-induced increase
glucose insulin augment treatment-induced increase High glucose concentrations (25 mM)

S616-p - IRS1 (human) ▲
Orthologous residues
IRS1 (human): S616‑p, IRS1 (mouse): S612‑p, IRS1 (rat): S612‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase High glucose concentrations (25 mM)
azaserine glucose inhibit treatment-induced increase
glucosamine increase
PD98059 glucosamine inhibit treatment-induced increase

Y632-p - IRS1 (human) ▲
Orthologous residues
IRS1 (human): Y632‑p, IRS1 (mouse): Y628‑p, IRS1 (rat): Y628‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
glucosamine insulin inhibit treatment-induced increase
glucose insulin augment treatment-induced increase High glucose concentrations (25 mM)

S473-p - Akt1 (rat) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
glucosamine insulin inhibit treatment-induced increase

T203-p - ERK1 (rat) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase High glucose concentrations (25 mM)
azaserine glucose inhibit treatment-induced increase
glucosamine glucose augment treatment-induced increase
JNK inhibitor I glucosamine inhibit treatment-induced increase

Y205-p - ERK1 (rat) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase High glucose concentrations (25 mM)
azaserine glucose inhibit treatment-induced increase
glucosamine glucose augment treatment-induced increase
JNK inhibitor I glucosamine inhibit treatment-induced increase

T183-p - ERK2 (rat) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase High glucose concentrations (25 mM)
azaserine glucose inhibit treatment-induced increase
glucosamine glucose augment treatment-induced increase
JNK inhibitor I glucosamine inhibit treatment-induced increase

Y185-p - ERK2 (rat) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase High glucose concentrations (25 mM)
azaserine glucose inhibit treatment-induced increase
glucosamine glucose augment treatment-induced increase
JNK inhibitor I glucosamine inhibit treatment-induced increase

T183-p - JNK1 (rat) ▲
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase High glucose concentrations (25 mM)
azaserine glucose inhibit treatment-induced increase
glucosamine glucose augment treatment-induced increase
JNK inhibitor I glucosamine inhibit treatment-induced increase

Y185-p - JNK1 (rat) ▲
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase High glucose concentrations (25 mM)
azaserine glucose inhibit treatment-induced increase
glucosamine glucose augment treatment-induced increase
JNK inhibitor I glucosamine inhibit treatment-induced increase

T183-p - JNK2 (rat) ▲
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase High glucose concentrations (25 mM)
azaserine glucose inhibit treatment-induced increase
glucosamine glucose augment treatment-induced increase
JNK inhibitor I glucosamine inhibit treatment-induced increase

Y185-p - JNK2 (rat) ▲
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase High glucose concentrations (25 mM)
azaserine glucose inhibit treatment-induced increase
glucosamine glucose augment treatment-induced increase
JNK inhibitor I glucosamine inhibit treatment-induced increase

S63-p - Jun (rat) ▲
Orthologous residues
Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glucose increase High glucose concentrations (25 mM)
azaserine glucose inhibit treatment-induced increase
glucosamine glucose augment treatment-induced increase
JNK inhibitor I glucosamine inhibit treatment-induced increase

S2448-p - mTOR (rat) ▲
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
glucosamine insulin inhibit treatment-induced increase

T412-p - p70S6K (rat) ▲
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
glucosamine insulin inhibit treatment-induced increase

T1466-p - TSC2 (rat) ▲
Orthologous residues
TSC2 (human): T1462‑p, TSC2 iso3 (human): T1418‑p, TSC2 iso4 (human): T1439‑p, TSC2 (mouse): T1465‑p, TSC2 iso6 (mouse): T1443‑p, TSC2 (rat): T1466‑p, TSC2 iso2 (rat): T1423‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  RIN (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
glucosamine insulin inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.